Omeros (OMER) Change in Accured Expenses (2010 - 2026)
Omeros (OMER) reported Change in Accured Expenses of -$979000.0 for Q1 2026, up 80.58% on a YoY basis from -$542132.7 in Q1 2025, and up 44.15% sequentially from -$1.8 million in Q4 2025.
Omeros (OMER) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Change in Accured Expenses data on file, last reported at -$979000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 80.58% year-over-year to -$979000.0; the trailing twelve-month figure through Mar 2026 stood at $8.6 million (up 263.61% YoY), and the FY2025 full-year result was $4.6 million, up 187.46% from the prior year.
- Change in Accured Expenses rose to -$979000.0 in Q1 2026, from -$1.8 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $8.2 million in Q2 2025 to a low of -$15.7 million in Q1 2022.
- A 5-year average of -$448176.5 and a median of $879000.0 in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses plunged 781.72% in 2024 and jumped 1336.43% in 2025, its largest moves.
- Tracing OMER's Change in Accured Expenses over 5 years: stood at $879000.0 in 2022, then increased by 7.05% to $941000.0 in 2023, then soared by 544.63% to $6.1 million in 2024, then slumped by 128.9% to -$1.8 million in 2025, then soared by 44.15% to -$979000.0 in 2026.
- Business Quant data shows OMER's Change in Accured Expenses at -$979000.0 in Q1 2026, -$1.8 million in Q4 2025, and $3.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | Omeros | 810.87 Mn | 810.87 Mn | 9.31 Mn | -979,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -979,000.00 |
| Mar 31, 2026 | -979,000.00 |
| Dec 31, 2025 | -1.75 Mn |
| Dec 31, 2025 | -1.75 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 8.25 Mn |
| Jun 30, 2025 | 8.25 Mn |
| Mar 31, 2025 | -5.04 Mn |
| Mar 31, 2025 | -5.04 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Sep 30, 2024 | -5.64 Mn |
| Sep 30, 2024 | -5.64 Mn |
| Jun 30, 2024 | -667,000.00 |
| Jun 30, 2024 | -667,000.00 |
| Mar 31, 2024 | -5.00 Mn |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | 941,000.00 |
| Dec 31, 2023 | 941,000.00 |